For Vertex these days, it’s all about the launches of three new products—sickle cell disease gene therapy Casgevy, the ...

The drug, shown to be almost as effective as opioids for short-term pain, is the first fundamentally new kind of painkiller ...

Vertex Pharmaceuticals is working toward making its recently approved non-opioid pain medicine Journavx not only broadly ...

The FDA on Thursday approved a new class of pain medication that provides an alternative to opioids. It will be sold under ...

The FDA has approved Journavx, a pain medication, offering a safer alternative to opioids. Learn about its benefits and side ...

A new painkiller that is said to be free of addiction risks may be transformative for treatment of acute pain, according to ...

If the attention generated by BioSpace’s coverage of this landmark approval is any indication, Americans are hungry for ...

Journavx can be taken with ibuprofen for its anti-inflammatory effects. The prescription medication is not in pharmacies yet, but it maybe there by the end of February. Click here to report a typo.

The Food and Drug Administration (FDA) has approved Journavx™ (suzetrigine) for the treatment of moderate to severe acute pain in adults.

The new non-opioid drug has been approved for the treatment of severe pain, such as that following surgery or an injury.

The drug, suzetrigine, will be sold under the brand name Journavx and is the first new class of pain medicine approved in more than 20 years. “Today’s approval is an important public health ...

Now a third option is available after the U.S. Food and Drug Administration last week approved Vertex Pharmaceuticals’ Suzetrigine, sold as twice-daily Journavx, a non-addictive ...